Monitor for NDA resubmission timing updates and FDA reinspection progress at the current contract manufacturer. The dual-source manufacturing strategy introduces optionality but also potential delays if the U.S.-based site requires 12 months of stability data.
Price Chart
Executive Summary
Grace Therapeutics reported a net loss of $15.8M for Q1 FY2027 (June 30, 2026), driven by a $13.5M impairment of IPR&D for deprioritized assets GTx-101/GTx-102, while the core GTx-104 program remains on track for NDA resubmission with a dual-source manufacturing strategy. The company extended cash runway through end of calendar 2028 via a $10M private placement, but the GAAP EPS of -$0.91 is a large miss versus the consensus estimate of -$0.18, though the impairment is non-cash and the Street-convention EPS (excluding impairment) would be closer to -$0.06, which beats consensus.
Key Financial Metrics
Key Facts
- Net loss of $15.8M for Q1 FY2027 vs $3.4M in prior year, primarily due to $13.5M impairment of IPR&D for GTx-101/GTx-102.
- GAAP EPS of -$0.91 vs consensus -$0.18 (large miss), but excluding the impairment, operating loss was ~$2.4M, implying Street EPS near -$0.06 (beat).
- Cash and cash equivalents of $22.2M as of August 11, 2026, with runway through end of calendar 2028.
- NDA resubmission for GTx-104 remains on track; dual-source manufacturing strategy underway with two contract manufacturers.
- FDA CRL identified no clinical safety/efficacy issues; remaining items are CMC and non-clinical data.
- $10M private placement completed with new and existing institutional investors.
Financial Impact
Net loss of $15.8M, including $13.5M non-cash impairment; cash used in operations ~$3.2M; cash runway extended to end of 2028.
Risk Factors
- NDA resubmission timing uncertain and could be delayed beyond current expectations.
- FDA reinspection of current contract manufacturer is outside company control and could extend timeline.
- Potential need for additional capital if cash burn accelerates or resubmission is delayed beyond 2028.
- Impairment of GTx-101/GTx-102 signals full pivot to GTx-104, reducing pipeline optionality.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344442 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 6w ago | Insider Cluster | $2.26 $2.22 | ▼ −1.77% | ▼ −2.62% | $1.93 (−14.60%) |
Aug 13, 2026 10w ago | 8-K | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 13, 2026 10w ago | Press Release | $2.07 $2.16 | ▲ +4.35% | ▲ +4.55% | $1.93 (−6.76%) |
Aug 4, 2026 11w ago | Press Release | $2.14 $2.12 | ▼ −0.93% | ▼ −0.77% | $1.93 (−9.81%) |
Jul 28, 2026 12w ago | 8-K | $2.25 $2.08 | ▼ −7.56% | ▼ −6.02% | $1.93 (−14.22%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▼ −5.04% | ▼ −4.73% | $1.93 (−18.91%) |
Jun 18, 2026 18w ago | 8-K | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 18, 2026 18w ago | Press Release | $2.38 $2.26 | ▲ +5.04% | ▲ +4.73% | $1.93 (+18.91%) |
Jun 5, 2026 20w ago | 8-K | $2.30 $2.33 | ▲ +1.30% | ▲ +1.60% | $1.93 (−16.09%) |
Apr 27, 2026 26w ago | 8-K | $2.16 $2.10 | ▲ +2.78% | ▲ +2.29% | $1.93 (+10.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers